GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Other Current Receivables

Incanthera (AQSE:INC) Other Current Receivables : £0.00 Mil (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Incanthera Other Current Receivables?

Incanthera's Other Current Receivables for the quarter that ended in Sep. 2023 was £0.00 Mil.

Incanthera's annual Other Current Receivables stayed the same from Mar. 2021 (£0.00 Mil) to Mar. 2022 (£0.00 Mil) but then increased from Mar. 2022 (£0.00 Mil) to Mar. 2023 (£0.01 Mil).


Incanthera Other Current Receivables Historical Data

The historical data trend for Incanthera's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Other Current Receivables Chart

Incanthera Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Other Current Receivables
- - - 0.01

Incanthera Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Other Current Receivables Get a 7-Day Free Trial - - - 0.01 -

Incanthera Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Incanthera Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Incanthera's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Incanthera (AQSE:INC) Business Description

Traded in Other Exchanges
N/A
Address
76 King Street, Manchester, GBR, M2 4NH
Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines